
<html>

<head>





</head>

<body lang="EN-US" link="blue" vlink="purple">

<div style="font-family:Times New Roman;">

<p align="right" style="margin:0in 0in .0001pt 74.75pt;text-align:right;text-indent:-74.75pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT
99.1</font></b></p>

<p style="margin:0in 0in .0001pt 74.75pt;text-indent:-74.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<h1 style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:auto;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">CONTACT:&#160; Pamela L. Dull, Sonus Pharmaceuticals, (425)
487-9500, Ext. 255</font></b></h1>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<h1 style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:auto;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sonus
Pharmaceuticals Modifies Terms for Proposed Acquisition of Synt:em</font></b></h1>

<h1 style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:auto;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:normal;">&nbsp;</font></b></h1>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">BOTHELL,
WA&#151;December&nbsp;28, 2004&#151;</font></b>Sonus Pharmaceuticals, Inc.
(Nasdaq:SNUS) and Synt:em, S.A., a privately held biopharmaceutical company
located in Nimes, France, today announced that they have revised the terms for
Sonus&#146; proposed acquisition of Synt:em, which had been announced on November&nbsp;3,
2004.</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Highlights of the new agreement include:</font></p>

<p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Sonus
will issue a maximum of 5.4 million shares to acquire 100% of the outstanding
shares of Synt:em, compared to the issuance of between 7.6 million and 8.9
million of Sonus shares under the previous agreement.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>The
new terms include the issuance of Sonus shares at closing having an approximate
value of $12 million.&#160; The remaining
Sonus shares will be issued upon achievement of contingent milestones based on
Synt:em product candidates entering Phase 2 clinical trials, as compared to
Phase 1 trials under the previous agreement.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Under
the new agreement, should the contingent milestone payments be earned, Synt:em
shareholders would own 20% of the combined entity, based upon the number of
shares of Sonus common stock outstanding today, which compares to ownership of
26% to 29% under the previous agreement should milestones have been met.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>The
new agreement also includes a mechanism to reallocate a portion of the Sonus
shares issued at transaction closing to the contingent milestone pool should
Sonus reach agreement with the U. S. Food and Drug Administration (FDA) on
Phase 3 testing or enter into a corporate partnership for TOCOSOL<font face="Symbol">&#210;</font>
Paclitaxel, the Company&#146;s lead cancer product.&#160;
The previous agreement had no such mechanism.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Board of Directors of
Sonus and Synt:em shareholders have unanimously approved the revised terms of
the acquisition agreement.&#160; The
transaction is targeted to close in the first quarter of 2005 and is subject to
approval by the shareholders of Sonus and other customary closing conditions.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;The strategic rationale
for combining Sonus and Synt:em remains compelling.&#160; This acquisition brings together two highly
complementary companies and represents an outstanding opportunity to expand
Sonus&#146; potential product portfolio and technology capabilities, both of which
will increase long-term shareholder value,&#148; said Michael A. Martino, President
and Chief Executive Officer of Sonus Pharmaceuticals.&#160; &#147;Since announcing the proposed Synt:em
acquisition, we have gained further clarity on the regulatory strategy for
TOCOSOL Paclitaxel following an end of Phase 2 meeting with the FDA in
December.&#160; It therefore was appropriate
to amend the original terms to more accurately reflect the increased value of
Sonus&#146; anticipated achievement of pending milestones for TOCOSOL Paclitaxel.&#148;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In September&nbsp;2004,
Sonus requested and was subsequently granted a meeting with the FDA to discuss
its Phase 3 plans for TOCOSOL Paclitaxel.&#160;
On December&nbsp;21, the Company reported under Form 8-K that it had
recently met with the Agency, and based on preclinical and clinical data
generated to date, the FDA indicated that it is appropriate to pursue Phase 3
testing and submission of a TOCOSOL Paclitaxel New Drug Application (NDA) under
a 505(b)(2) regulatory mechanism, as per Sonus&#146; stated objective.&#160; The FDA&#146;s use of 505(b)(2) is designed to</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\jgafar\04-15370-1\task263485\15370-1-mm.htm',USER='agarahim',CD='Dec 28 12:03 2004' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">streamline the NDA review
process by not requiring duplicate work.&#160;
The 505(b)(2) approval path will rely on the FDA&#146;s previous findings of
safety and efficacy for Taxol</font><font face="Symbol">&#210;</font>,
the reference paclitaxel product, supplemented by additional data supporting
TOCOSOL Paclitaxel&#146;s efficacy and safety.</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About
Sonus Pharmaceuticals, Inc.</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Headquartered near
Seattle, Sonus Pharmaceuticals is focused on the development of novel drugs for
the treatment of cancer that offer improved administration, tolerability,
safety and effectiveness.&#160; The Company&#146;s
lead product is TOCOSOL Paclitaxel, a novel formulation of the leading
anti-cancer drug paclitaxel.&#160; With
patient enrollment complete in Phase 2a studies of TOCOSOL Paclitaxel, and
Phase 2b studies ongoing, Sonus continues to advance the product toward Phase 3
testing.&#160; In addition to executing its
plans for TOCOSOL Paclitaxel, the Company remains focused on driving product
and corporate development activities towards building and expanding its
pipeline of oncology product candidates.&#160;
For additional information, including news releases, please visit Sonus&#146;
web site at www.sonuspharma.com.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About
Synt:em, S.A.</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Located in Nimes and
Montpellier, France, Synt:em was founded in 1995 to discover and develop novel
drugs that address unmet medical needs in cancer, pain management and diseases
affecting the central nervous system.&#160;
The company has approximately 40 employees.&#160; Additional information about Synt:em is
available at www.syntem.com.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<h1 align="left" style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:auto;text-align:left;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">Safe
Harbor</font></b></h1>

<h1 align="left" style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:auto;text-align:left;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:normal;">&nbsp;</font></b></h1>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certain statements made
in this press release are forward-looking such as those, among others, relating
to the development, safety and efficacy of drug delivery products and potential
applications for these products.&#160; As
discussed in Sonus Pharmaceuticals&#146; filings with the Securities and Exchange
Commission, including its Annual Report on Form 10-K filed on March&nbsp;12,
2004 and Quarterly Report on Form 10-Q filed November&nbsp;15, 2004, actual
results could differ materially from those projected in the forward-looking
statements as a result of the following factors, among others:&#160; the Company&#146;s and Synt:em&#146;s products will
require extensive clinical testing and approval by regulatory authorities; such
approvals are lengthy and expensive and may never occur; risks that clinical
studies with TOCOSOL Paclitaxel will not be successful; risks that the FDA may
not approve the Company&#146;s proposed New Drug Application; risks that the Company
may not be able to effectively or completely integrate the business and
operations of Synt:em; risks that the combined company may not be able raise
capital to finance the increased costs of the business and operations of both
companies; and risks of successful development of additional drug delivery products.&#160; Sonus undertakes no obligation to update the
forward-looking statements contained herein or to reflect events or
circumstances occurring after the date hereof.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">###</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Additional
Information about the Acquisition</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sonus will file a proxy
statement and other documents concerning the proposed acquisition of Synt:em
with the Securities and Exchange Commission.<b><font style="font-weight:bold;">&#160; Sonus stockholders are urged to read the
proxy statement when it becomes available and other relevant documents filed
with the SEC because they will contain important information.&#160; </font></b>A copy of the proxy statement will
be mailed to the stockholders of Sonus.&nbsp; Sonus stockholders may obtain a
free copy of the proxy statement and other relevant documents filed by Sonus
with the SEC when they become available at the SEC&#146;s website at
www.sec.gov.&#160; The proxy statement and
these other documents may also be obtained for free from Sonus by directing a
request to:&#160; Investor Relations, 22026
20th Avenue S.E., Bothell, Washington, 98021, telephone number (425) 487-9500.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sonus and its directors,
executive officers and certain of its employees may be deemed to be
participants in the solicitation of proxies from the stockholders of Sonus with
respect to the proposed transaction.&nbsp; Information regarding the names, affiliations
and interests of the participants in the solicitation will be included in the
proxy statement.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\jgafar\04-15370-1\task263485\15370-1-mm.htm',USER='agarahim',CD='Dec 28 12:03 2004' -->


</body>

</html>

